Teva: 'Too early' to say whether merger triggers job cuts

Teva Pharmaceutical Industries ($TEVA) says recent reports of up to 1,500 job cuts from the integration of its recent acquisition, Cephalon, "came from unsubstantiated sources." A U.S. spokeswoman told the Daily Local it's too early to know how the merger will affect Teva and Cephalon employees. Report